Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions June 30 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Tuesday:
** British lender Barclays BARC.L acquired a 999-year leasehold interest in its global headquarters at London's Canary Wharf in a deal valued at £750 million ($992.78 million). nL6N4320ER
** India's Adani Ports and Special Economic Zone APSE.NS said that Switzerland's MSC Group will acquire a 49% stake in its Vizhinjam port for $1.4 billion, in what it said is the largest foreign private investment in domestic port infrastructure. nL4N43208V
** Digital Realty DLR.N will acquire a larger stake in three data centers in Northern Virginia from asset manager Blackstone BX.N in a $3.5 billion cash-and-stock deal, the companies said on Monday. nL4N4311JL
** World Insurance Associates has acquired the business of Brooklyn, New York-based Fillmore Insurance Agency. nL6N4310YB
** Rocket Lab RKLB.O struck an $8 billion deal to acquire satellite communications provider Iridium Communications IRDM.O on Monday, betting on a SpaceX-style advantage that combines a constellation of satellites with the in-house rockets that will launch them. nL6N4310O4
** ANV Group Holdings has entered into a definitive agreement to acquire specialist MGA Assured Underwriting Group Limited (AUG) from UK-based private equity firm Mobeus. nL6N4310ZX
** Private equity firm CVC CVC.AS on Monday said it had agreed to buy Italian dessert ingredients maker IRCA from rival fund Advent International, as consumer-focused businesses defy the disruption caused by artificial intelligence and the Middle East crisis. nL6N4310JA
** Martin Marietta Materials MLM.N said on Monday it would merge with limestone supplier Lhoist North America in a cash-and-stock deal worth $13.5 billion, as the building materials firm looks to tap growing demand for lime products. nL4N4310UP
** Zymeworks ZYME.O said on Monday it will acquire Theravance Biopharma TBPH.O for $929 million in cash, marking the oncology-focused drugmaker's entry into the highly competitive respiratory disease segment. nL4N4310R7
(Compiled by Rajarshi Roy in Bengaluru)